Share on StockTwits

Qiagen NV (NASDAQ:QGEN) has received an average rating of “Hold” from the fourteen ratings firms that are currently covering the company, American Banking and Market News reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $24.48.

Qiagen NV (NASDAQ:QGEN) opened at 24.01 on Tuesday. Qiagen NV has a 52 week low of $19.46 and a 52 week high of $25.32. The stock’s 50-day moving average is $24.44 and its 200-day moving average is $22.67. The company has a market cap of $5.586 billion and a P/E ratio of 43.42.

Qiagen NV (NASDAQ:QGEN) last announced its earnings results on Tuesday, July 29th. The company reported $0.26 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.25 by $0.01. The company had revenue of $331.20 million for the quarter, compared to the consensus estimate of $330.76 million. During the same quarter last year, the company posted $0.27 earnings per share. Qiagen NV’s revenue was up 4.7% compared to the same quarter last year. Analysts expect that Qiagen NV will post $1.08 EPS for the current fiscal year.

QGEN has been the subject of a number of recent research reports. Analysts at Barclays reiterated an “equal weight” rating on shares of Qiagen NV in a research note on Tuesday, August 5th. They now have a $24.00 price target on the stock, up previously from $19.00. Separately, analysts at Wedbush raised their price target on shares of Qiagen NV from $19.00 to $20.00 in a research note on Thursday, July 31st. They now have a “neutral” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Qiagen NV from $19.00 to $23.00 in a research note on Thursday, July 31st.

QIAGEN N.V., (NASDAQ:QGEN) is a holding company, which provides sample and assay technologies.

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with Analyst Ratings Network's FREE daily email newsletter.